Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
作者信息
Croda Julio, Ranzani Otavio T
机构信息
Universidade Federal de Mato Grosso do Sul, Campo Grande, 79081-746, Brazil; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain; Pulmonary Division, Heart Institute (InCor), HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, Brazil.
出版信息
Lancet Infect Dis. 2022 Apr;22(4):430-432. doi: 10.1016/S1473-3099(21)00696-4. Epub 2021 Dec 8.
Abstract
摘要
相似文献
1
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
Lancet Infect Dis. 2022 Apr;22(4):430-432. doi: 10.1016/S1473-3099(21)00696-4. Epub 2021 Dec 8.
2
mRNA COVID-19 Vaccine Booster After Inactivated Vaccine Primary Series.
JAMA. 2022 Jun 21;327(23):2280. doi: 10.1001/jama.2022.9408.
3
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
J Med Virol. 2022 Jan;94(1):35-38. doi: 10.1002/jmv.27334. Epub 2021 Sep 22.
4
Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.
Pediatr Infect Dis J. 2005 Jan;24(1):70-7. doi: 10.1097/01.inf.0000148923.46453.48.
5
Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
Pediatr Infect Dis J. 2000 May;19(5):417-23. doi: 10.1097/00006454-200005000-00006.
6
Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Pediatr Infect Dis J. 2012 Jan;31(1):e24-30. doi: 10.1097/INF.0b013e318242460a.
7
A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
Pediatr Infect Dis J. 2017 Nov;36(11):e272-e282. doi: 10.1097/INF.0000000000001682.
8
Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Pediatr Infect Dis J. 1998 Apr;17(4):294-304. doi: 10.1097/00006454-199804000-00006.
9
Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
Southeast Asian J Trop Med Public Health. 2012 Mar;43(2):442-54.
10
Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
JAMA. 2022 Jul 19;328(3):234. doi: 10.1001/jama.2022.11844.
引用本文的文献
1
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil.
Lancet Reg Health Am. 2025 Feb 22;44:101031. doi: 10.1016/j.lana.2025.101031. eCollection 2025 Apr.
2
Global disparities in COVID-19 vaccine booster dose (VBD) acceptance and hesitancy: An updated narrative review.
Vaccine X. 2024 Mar 23;18:100480. doi: 10.1016/j.jvacx.2024.100480. eCollection 2024 Jun.
3
Comparative Analysis of IgG Antibody Titers Induced by Three Different SARS-COV-2 Vaccines in Healthy Adults of Pakistan.
Curr Microbiol. 2023 Oct 16;80(12):373. doi: 10.1007/s00284-023-03485-9.
4
Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
Front Public Health. 2023 Aug 24;11:1229045. doi: 10.3389/fpubh.2023.1229045. eCollection 2023.
5
SARS-CoV-2 variants of concerns in animals: An unmonitored rising health threat.
Virusdisease. 2022 Dec;33(4):466-476. doi: 10.1007/s13337-022-00794-8. Epub 2022 Nov 10.
6
Current clinical status of new COVID-19 vaccines and immunotherapy.
Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5.
7
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Sci Rep. 2022 Jul 14;12(1):12038. doi: 10.1038/s41598-022-16097-3.
8
The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study.
Lancet Reg Health West Pac. 2022 Apr;21:100389. doi: 10.1016/j.lanwpc.2022.100389. Epub 2022 Feb 3.
9
Managing waning vaccine protection against SARS-CoV-2 variants.
Lancet. 2022 Jan 1;399(10319):2-3. doi: 10.1016/S0140-6736(21)02841-5. Epub 2021 Dec 20.
本文引用的文献
1
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8.
2
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
Emerg Microbes Infect. 2021 Dec;10(1):2125-2127. doi: 10.1080/22221751.2021.1996210.
3
China's COVID vaccines have been crucial - now immunity is waning.
Nature. 2021 Oct;598(7881):398-399. doi: 10.1038/d41586-021-02796-w.
4
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
5
CoronaVac induces lower neutralising activity against variants of concern than natural infection.
Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.
6
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
BMJ. 2021 Aug 20;374:n2015. doi: 10.1136/bmj.n2015.
7
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
Lancet Microbe. 2021 Oct;2(10):e527-e535. doi: 10.1016/S2666-5247(21)00129-4. Epub 2021 Jul 8.
8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
Zotero 插件